Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Asian markets take a breather
Fri, 16 Dec 09:30 am

Most major Asian stock markets have taken a breather and opened the day in the green with stock markets in Indonesia (up 1.1%), South Korea (up 0.7%) and Hong Kong (up 0.6%) leading the gains. The Indian stock markets have also opened the day on a firm note. Stocks in the realty and auto space are the biggest gainers.

The BSE-Sensex is trading higher by 109 points (0.7%), while the NSE-Nifty is up by around 47 points (1%). Mid cap and small cap stocks are trading in the green as well, with the BSE Mid Cap and BSE Small Cap cap indices up by 0.6% and 0.5% respectively. The rupee is trading at 52.66 to the US dollar.

Auto stocks have opened the day on a strong note with Tata Motors, Ashok Leyland and Mahindra & Mahindra (M&M) leading the gains. Tata Motors has announced that its global sales have increased by 35% year-on-year (YoY) in November 2011 to 108,028 units despite the slowdown that has gripped most of the world. Sales of luxury brands from Jaguar Land Rover were higher by 27% YoY at 29,183 units during the period. Sales of luxury sedans of Jaguar brand declined by 5% YoY in November to 5,315 units. The sales of Land Rover witnessed a rise of 38% YoY to 23,868 units. Total passenger vehicles sales stood at 58,304 units in November 2011, a 47% YoY surge. On the other hand, commercial vehicles sales were up by 24% YoY to 49,724 units. The Tata Motors Group's global sales include Tata, Tata Daewoo and Hispano Carrocera range of commercial vehicles, Tata passenger vehicles, along with the distributed brands in India, Jaguar and Land Rover.

Indian Pharma stocks have opened the day in the firm note with Glenmark Pharmaceuticals, Orchid Chemical and Aurobindo Pharma trading firm. Glenmark Pharmaceuticals has planned to go ahead with the launch of Crofelemer even after it is facing issues with Napo Pharma who has claimed the termination of the deal with Glenmark. Crofelemer is the medicine used for treatment of diarrhea in HIV positive patients. Glenmark has initiated a filing for Crofelemer after Salix Pharma announced a new drug application for Crofelemer to the US Food and Drug Administration (US FDA). The company's management said that they were waiting for Salix Pharma to file the new drug application for Crofelemer which will be used by the company to start the filing process. Crofelmer is expected to be launched in 140 emerging nations by Glenmark.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Asian markets take a breather". Click here!

1 Responses to "Asian markets take a breather"

gsravikumar

Dec 16, 2011

Above article is good and informative.
what will be the effect of proposed green cess on the motor inustries, shares?

Like 
  
Equitymaster requests your view! Post a comment on "Asian markets take a breather". Click here!
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.